New ideas on the therapeutic effect of a combination of vaccines against pneumococcal, Haemophilus influenzae type b infection, and influenza in patients with chronic obstructive pulmonary disease

Kostinov, M. P.; Жестков, А В; Протасов, А. Д.; Магаршак, О О; Костинова, Т. А.

doi:10.17116/terarkh201587317-22

Cited by 4 publications

(1 citation statement)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While most evidence for the benefits of vaccination in COPD patients comes from studies in higher-income countries, studies looking specifically at LMICs have also found that influenza vaccination is beneficial and cost-effective [108]. The benefits of a comprehensive vaccination program can be substantial: one Russian study in patients with COPD found combination vaccination against pneumococcal infection, Haemophilus influenza type b infection, and influenza resulted in a 3.7-fold reduction in COPD exacerbations and a 3.4-fold decrease in antibiotic use in the year-long followup period [109].…”

Section: Beyond Infectious Diseasevaccination As An Important Tool Fomentioning

confidence: 99%

Challenges in adult vaccination

2018

View full text Add to dashboard Cite

Life-long primary prevention interventions beginning and continuing throughout an individual's lifetime are increasingly seen as key to meeting the global healthcare challenges that accompany demographic changes - a concept referred to as "Healthy aging". In this perspective, vaccination is seen as part of a triad, together with healthy diet and exercise. Current adult vaccine coverage is lower than target vaccination rates in most developed countries, and so vaccine preventable diseases continue to present a substantial burden on health and healthcare resources, especially in older individuals. In part, this is due to lack of knowledge and understanding of the benefits of vaccination, inconsistent recommendations by providers and uncertainties about cost benefits. However, lower vaccine effectiveness in older adults plays a part, and new vaccines with novel characteristics to improve effectiveness in older adults are required. A life-course immunization approach to ensure optimal vaccine uptake across adults of all ages can be expected to reduce morbidity and mortality in later life. To achieve this, greater emphasis on public and healthcare provider education is necessary, based on appropriate economic analyses that demonstrate the overall value of vaccination. This article introduces the technical, economic, political and demographic issues that make establishing effective adult vaccination programs such a difficult, but pressing issue, and outlines some of the steps that are now being taken to address them. Key messages Life-long preventive activities that start and continue throughout life are essential, especially as the world's population is "getting older". This "Healthy aging" approach includes not only healthy diet and physical exercise; vaccination is critical in reducing some infectious diseases and their complications. Many adults, especially older adults (who have lower immunity than younger people) develop infections such as influenza and shingles that could potentially be prevented through vaccination. This review provides a perspective on the challenges in delivering a life-course immunization program. While some vaccines are less effective in older people, newer vaccines have been developed which provide stronger and longer protection in older patients than standard existing vaccines. However, the benefits of vaccination can only be realized if the vaccines are recommended and used. For that purpose, greater education of patients and their healthcare providers is necessary. Better knowledge of vaccines and making sure that all adults are up to date with all their recommended vaccines is an essential part of "Healthy aging". This should prevent not only vaccine-preventable diseases but also reduce the risk of complications in later life.

show abstract

Section: Beyond Infectious Diseasevaccination As An Important Tool Fomentioning

confidence: 99%

Challenges in adult vaccination

2018

View full text Add to dashboard Cite

show abstract

Choice of optimal vaccination tactics against pneumococcal infection from immunological and clinical standpoints in patients with chronic obstructive pulmonary disease

Протасов

et al. 2016

Ter. arkh.

Self Cite

View full text Add to dashboard Cite

If patients with COPD need to be vaccinated against pneumococcal infection, preference should be given to PCV13 monovaccination. Short-term observations have shown that the sequential use of pneumococcal conjugate and polysaccharide vaccines is redundant and gives no additional benefit to patients with COPD. However, the sequential application of both vaccines may have additional advantages in the long term.

show abstract

Cost-effectiveness of vaccination against pneumococcal infection of adults at risk within the federal and regional programs

Рудакова

Брико

Лобзин³

et al. 2019

test

Self Cite

View full text Add to dashboard Cite

Резюме Цель: оценка эффективности затрат на вакцинацию 13-валентной пневмококковой конъюгированной вакциной (ПКВ13) и ее сочетанием с 23-валентной пневмококковой полисахаридной вакциной (ППВ23) иммунокомпетентных взрослых пациентов с различным уровнем риска пневмококковой инфекции. Материалы и методы: анализ эффективности затрат осуществляли методом моделирования с горизонтом 15 лет с позиции системы здравоохранения и с учетом социальной перспективы. Анализ проводили для 20-, 40-и 60-летних пациентов с 1, 2 и 3 факторами риска. В соответствии с национальными рекомендациями режим вакцинации предполагал введение 1 дозы ПКВ13

show abstract

New ideas on the therapeutic effect of a combination of vaccines against pneumococcal, Haemophilus influenzae type b infection, and influenza in patients with chronic obstructive pulmonary disease

Cited by 4 publications

References 1 publication

Challenges in adult vaccination

Challenges in adult vaccination

Choice of optimal vaccination tactics against pneumococcal infection from immunological and clinical standpoints in patients with chronic obstructive pulmonary disease

Cost-effectiveness of vaccination against pneumococcal infection of adults at risk within the federal and regional programs

Contact Info

Product

Resources

About